1383446-20-5

Basic information

• Product Name: N-((1R,3S)-3-((5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide
• Synonyms: N-((1R,3S)-3-((5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide
• CAS NO: 1383446-20-5
• Molecular Weight: 677.784
• Mol File: 1383446-20-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((1R,3S)-3-((5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((1R,3S)-3-((5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide(1383446-20-5)
• EPA Substance Registry System: N-((1R,3S)-3-((5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide(1383446-20-5)

Safety Data

• Hazardous Substances Data: 1383446-20-5(Hazardous Substances Data)

Upstream product

• 1383446-28-3 3-bromo-1-trityl-pyrazolo[3,4-b]pyridine 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 68618-36-0 3-Bromo-1H-pyrazolo<3,4-b>pyridine 
• 36404-90-7 2-fluoropyridine-3-carboxaldehyde 

Downstream Products

• 1383447-03-7 N-((1R,3S)-3-((5-fluoro-2-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide 

Relevant articles and documents

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.